Literature DB >> 8215285

Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium.

T Lazard1, C Perronne, J Grosset, J L Vilde, J J Pocidalo.   

Abstract

C57BL/6 mice were pretreated with rifabutin or clarithromycin alone or combined with minocycline 3 days before intravenous challenge (day 0) with Mycobacterium avium. Treatment was continued until sacrifice at days 1, 8, 15, and 21. Rifabutin or clarithromycin decreased the level of infection in both the lungs and the spleen. Rifabutin was as effective as clarithromycin in the lungs but was less [corrected] effective in the spleen. The clarithromycin-minocycline combination was as effective as clarithromycin alone.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8215285      PMCID: PMC188043          DOI: 10.1128/AAC.37.8.1690

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Clarithromycin-minocycline is synergistic in a murine model of toxoplasmosis.

Authors:  F G Araujo; P Prokocimer; J S Remington
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

Review 2.  Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution.

Authors:  J J Ellner; M J Goldberger; D M Parenti
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

3.  Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J J Pocidalo; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

4.  Effect of rifabutin on disseminated Mycobacterium avium infections in thymectomized, CD4 T-cell-deficient mice.

Authors:  S K Furney; A D Roberts; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

5.  Antimycobacterial activity in vivo of LM427 (rifabutin).

Authors:  I M Orme
Journal:  Am Rev Respir Dis       Date:  1988-11

6.  Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice.

Authors:  T Lazard; C Perronne; Y Cohen; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

7.  Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice.

Authors:  C Perronne; Y Cohen; C Truffot-Pernot; J Grosset; J L Vildé; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

8.  Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages.

Authors:  Y Cohen; C Perronne; C Truffot-Pernot; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

9.  Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS.

Authors:  F de Lalla; R Maserati; P Scarpellini; P Marone; R Nicolin; F Caccamo; R Rigoli
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

10.  Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial.

Authors:  B Dautzenberg; C Truffot; S Legris; M C Meyohas; H C Berlie; A Mercat; S Chevret; J Grosset
Journal:  Am Rev Respir Dis       Date:  1991-09
View more
  7 in total

1.  Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model.

Authors:  M Brun-Pascaud; P Rajagopalan-Levasseur; F Chau; G Bertrand; L Garry; F Derouin; P M Girard
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 2.  Beige mouse model for Mycobacterium avium complex disease.

Authors:  P R Gangadharam
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

3.  Mycobacterium avium complex infection in mice: lack of exacerbation after LP-BM5 murine leukemia virus infection.

Authors:  F Grassi; C Perronne; M Levacher-Clergeot; Y Cohen; C Maslo; F Chau; M Sinet; J J Pocidalo
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

4.  Use of normal C57BL/6 mice with established Mycobacterium avium infections as an alternative model for evaluation of antibiotic activity.

Authors:  Y Cohen; C Perronne; T Lazard; C Truffot-Pernot; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

5.  Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model.

Authors:  S K Furney; P S Skinner; J Farrer; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

Review 6.  Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; A Fitton
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

7.  An In Vitro Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies.

Authors:  Vidhisha V Sonawane; Mike M Ruth; Lian J Pennings; Elin M Svensson; Heiman F L Wertheim; Wouter Hoefsloot; Jakko van Ingen
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.